

Differential alteration in peripheral T-regulatory and T-effector cells with change in P-glycoprotein expression in Childhood Nephrotic Syndrome:

A longitudinal Study

<u>Akhilesh Jaiswal¹</u>, Narayan Prasad¹, Vikas Agarwal², Brijesh Yadav¹, D R Modi ,Saurabh Chaturvedi , Harshit Singh¹

Department of Nephrology¹ and Clinical Immunology²,
Sanjay Gandhi Postgraduate Institute of Medical Sciences,
Department of Biotechnology Babasaheb Bhimrao Ambedkar University, Lucknow, INDIA

Introduction

- Minimal Change Disease (MCD) is one of the most common glomerular disease causing idiopathic Nephrotic Syndrome (INS) in children.
- Idiopathic Nephrotic Syndrome responds to glucocorticoid therapy, however 60-80% of patients relapse.

Nasi M et al. Pediatric Kidney Disease 1992

MCD may be associated with T-cell disorder,

Shalhoub RJ, Lancet 1974;2:556-603

increase in inflammatory cytokines levels,

Giuliana L et al. Am J of Kid Diseases 2002; 39: 958-65
podocyte injury with effacement of foot process of podocytes and/or

Barisoni L et al. Clin J Am Soc Nephrol 2007;2:529-42

- Steroid non responsiveness may be because of disturbances in T cell subset population and/or,
- One of the factors of the acquired steroid resistance that could be modulate the disease response to pharmacological interventions, such as P-gp expression on immune cells and podocytes, suggest that P-gp may influence cell mediated immune response.

Klimecki et al Blood 1994;83:2451-245

 Patients of NS carrying homozygous mutants of single nucleotide polymorphism (SNP) G2677T/A are prone to develop steroid resistance.

Narayan Prasad et al NDT 2011;26:3968-74

- P-gp appears to be a double edged sword which protects the cells against the accumulation of xenobiotics and toxins in the cytoplasm
- Simultaneously by limiting cytosolic concentration, P-gp is capable of limiting the ability of steroids to bind to their receptors resulting in corticosteroid resistance.


Arthritis Rheum 2005; 52:1676-1683

Objectives

- ✓ To study the frequency of peripheral Treg, Th1 and Th2 lymphocytes and their respective cytokine level at baseline, when achieved remission and during relapse..
- ✓ To analyze the expression of P-gp and correlate with cytokine levels at baseline, when achieved remission and during relapse.

Materials and Methods

Flowchart of the Study



All patients were recruited as per criteria of ISKDC Prednisolone dose- 60 mg/m2/d prednisone for 6 weeks followed by 40 mg/m2/ alternate day

Remission- protein excretion <4 mg/m2/h or urine dipstix nil/trace for three consecutive days.

Relapse- protein excretion >40 mg/m2/h or urine dipstix ++ or more for three consecutive days

Stancid registance. Non responsiveness to 60 mg/m2/d prednicene for


Steroid resistance- Non responsiveness to 60 mg/m2/d prednisone for 4 weeks

Patients did not have underlying secondary causes

negative for hepatitis B surface antigen, anti hepatitis C virus,

human immunodeficiency virus seropositivity normal serum complement (C3 and C4) levels

Materials and Methods



Analysis of *In vitro* production of cytokines

and FoxP3

Acquired on Flow Cytometry (BD FACS Calibur)

PBMCs
were cultured
and supernatant was
analyzed for cytokines
(IFN-γ, IL-4, IL-10 and
TGF-β) by
ELISA

Results




Figure 1 | Results are expressed as the percentage of CD4+CD25+FoxP3+ Treg, CD4+IFN-Υ+ Th1 and CD4+IL-4+ Th2 cells in CD4+ lymphocyte in blood.




Figure2 | Cytokine levels in PBMC culture supernatants during follow up.

Characteristics	Baseline	Remissio n	Relapse	Control
Pgp % positive cells	8.69±3.62	5.46±3.14	10.02±5.2	4.89±1.73
RFI	8.22±1.82	6.72±1.88	8.65±2.96	7.13±5.26
RFI ×% positive cells	66.59±21.13	35.84±22.26	80.22±28.24	30.41±16.15

Table | P-glycoprotein, RFI and absolute P-gp expression on lymphocytes in different group of patients.

Results




Figure 3 | Absolute P-gp expressions at baseline, during remission, relapse in INS patients and control.




Figure 4| Correlation of absolute P-gp expression on peripheral blood lymphocytes with cytokines II-10, TGF- β , IFN- Υ and IL-4.




Figure 5 | T-regs frequency at baseline shows a trend towards significant and a significant difference at remission between relapsing and non-relapsing




Figure 6 | Absolute P-gp at remission was significantly higher in relapsing patients.

Conclusions

- ✓ Glucocorticoid therapy in INS induces decreased P-gp expression along with increased frequency and cytokine response of T-regulatory cells.
- ✓ Regulatory cytokines negatively correlates with P-gp expression may have a role in pharmacological interventions in NS patients.
- Monitoring of P-gp may help in the management of INS patients.



